Intermediate results of isolated mitral valve replacement with a Biocor porcine valve

Background: We analyzed the intermediate experience, survival, and prosthetic complications of patients who received the Biocor valve, a new-generation porcine valve, in the mitral position. Methods: At the University of Padua, between May 1992 and January 2004, 154 consecutive patients (102 female and 52 male patients; mean age, 72.3 6 years; age range, 37-86 years) received 158 mitral Biocor prostheses (Biocor Industria e Pesguisa Ltda, Belo Horizonte, Brazil). Thirty-five percent of the patients had previous mitral operations, 24% had coronary artery bypass grafting, and 34.6% had other procedures. Median preoperative New York Heart Association class was III. Echocardiography was performed in 75% of the long-term survivors. Follow-up included 609.4 patient-years and was 100% complete, with a median time of 4 patient-years (range, 0.02-11.3 years). At 8 years, 20 (14%) of 142 operative survivors were still at risk. Results: Early mortality was 13.6%. According to univariate analysis, New York Heart Association class III to IV, ejection fraction of less than 40%, urgency, male sex, and coronary artery bypass grafting were significant perioperative risk factors. Eight- and 10-year actuarial survival was 51.1% 5.6% (40 deaths). Eight-year actuarial freedom from valve-related death, thromboembolism, anticoagulantrelated hemorrhage, endocarditis, paravalvular leak, and valve-related complications were 85.2% 5%, 85.7% 4.4%, 92.6% 3.7%, 94.1% 3%, 91.8% 3%, and 70.2% 5.7%, respectively. Freedom from structural valve deterioration was 100%. Actual freedom from reoperation was 93.2% 2.2%. By Doppler echocardiography, the peak and mean transprosthetic gradients were 15 5 mmHg and 6.3 3 mm Hg, respectively (mean follow-up, 4.2 2.7 years). Conclusion: At intermediate follow-up, the Biocor prosthesis in the mitral position showed excellent results in terms of valve durability when compared with other second-generation tissue valves.